Viridian Therapeutics, Inc.
Every calculator, already run for VRDN
Open the full toolkit →You have the numbers on VRDN. Get the argument.
A written report on which of these readings actually decide the outcome for Viridian Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
17 analysts covering VRDNAnalyst Price Target Disagreement for Viridian Therapeutics, Inc.
Wall Street's bull case implies +158% from the current price; the bear case implies +13%. A 144% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for VRDN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comp…
VRDN — frequently asked
Is VRDN a buy right now?
Wall Street's consensus rating on Viridian Therapeutics, Inc. is Strong Buy across 17 analysts, with a mean price target of $36.75 (+89% vs. the current $19.40). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is VRDN's next earnings date?
Viridian Therapeutics, Inc. is next scheduled to report earnings around Nov 5, 2026. A full VRDN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Viridian Therapeutics, Inc.?
Analysts covering Viridian Therapeutics, Inc. (VRDN) range from a bear-case target of $22.00 to a bull-case high of $50.00, with a mean consensus target of $36.75 across 16 analysts. The spread of $28.00 (144% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Viridian Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Viridian Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full VRDN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Viridian Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.